Sosei Heptares Webinar Presentation for FY2021 Financial Results TOKYO, Japan and CAMBRIDGE, United Kingdom, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will announce its earnings results and present operational highlights...

Sosei Heptares and Verily will collaborate to generate novel drug candidates against GPCR targets for immune-mediated diseases Research agreement combines Verily’s proprietary Immune Profiler platform with Sosei Heptares’ world-leading StaR® (stabilized receptor) platform and structure-based drug design capabilities ...

Sosei Heptares to present at 40th Annual J.P. Morgan Healthcare Conference TOKYO, Japan and LONDON, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), today announced its Chief Financial Officer, Chris Cargill, will present at the 40th...

Sosei Heptares Announces Antitrust Clearance of License Agreement with Neurocrine Biosciences TOKYO, Japan and CAMBRIDGE, United Kingdom, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“Sosei Heptares”; TSE: 4565) today announces that in connection with the Collaboration and...

Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies against GPCR Targets Collaboration aims to combine Twist’s proprietary synthetic antibody libraries and sophisticated bioinformatics expertise with Sosei Heptares’ world-leading StaR® (stabilized receptor) platform to...